Targeting natural killer cell reactivity by employing antibody to Nkp46: Implications for type 1 diabetes

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Yossef, Rami ^a   Gur, Chamutal ^b,c   Shemesh, Avishai ^a   Guttman, Ofer ^a   Hadad, Uzi ^a   Nedvetzki, Shlomo ^d   Miletić, Antonija ^e   Nalbandyan, Karen ^f   Cerwenka, Adelheid ^g   Jonjic, Stipan ^e   Mandelboim, Ofer ^b   Porgador, Angel ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d BIOLINERX LTD   (Israel)

^e UNIVERSITY OF RIJEKA   (Croatia)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NCR1.15; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PLACEBO; STREPTOZOCIN; UNCLASSIFIED DRUG; BLOCKING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; GENE; GENE EXPRESSION REGULATION; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; MOUSE MODEL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NCR1 GENE; NONHUMAN; NONOBESE DIABETIC MOUSE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; RISK REDUCTION; SINGLE DRUG DOSE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; C57BL MOUSE; CELL CULTURE; DIABETES MELLITUS, EXPERIMENTAL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROTEIN TRANSPORT; TUMOR CELL LINE;

MURINAE; MUS;

ANIMALS; ANTIBODIES, BLOCKING; CELL LINE, TUMOR; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PROTEIN TRANSPORT;

EID: 84923785826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118936     Document Type: Article

References (46)

1. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008; 9: 503-510. doi: 10.1038/ni1582 PMID: 18425107
2. Shibuya A. Development and functions of natural killer cells. Int J Hematol.2003; 78: 1-6. PMID: 12894844
3. Colonna M, Jonjic S, Watzl C. Natural killer cells: fighting viruses and much more. Nat Immunol.2011; 12: 107-110. doi: 10.1038/ni0211-107 PMID: 21245897
4. Long EO. Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev.2008; 224: 70-84. doi: 10.1111/j.1600-065X.2008.00660.x PMID: 18759921
5. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature.1986; 319: 675-678. PMID: 3951539
6. Arnon TI, Markel G, Mandelboim O. Tumor and viral recognition by natural killer cells receptors. Semin Cancer Biol.2006; 16: 348-358. PMID: 16893656
7. Lam RA, Chwee JY, Le Bert N, Sauer M, Pogge von Strandmann E, Gasser S Regulation of self-ligands for activating natural killer cell receptors. Ann Med.2013; 45: 384-394. doi: 10.3109/07853890. 2013.792495 PMID: 23701136
8. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol.2001; 19: 197-223. PMID: 11244035
9. Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, et al. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol.2010; 11: 121-128. doi: 10. 1038/ni.1834 PMID: 20023661
10. Rodacki M, Milech A, de Oliveira JE. NK cells and type 1 diabetes. Clin Dev Immunol.2006; 13: 101-107. PMID: 17162353
11. Chandy KG, Charles MA, Buckingham B, Waldeck N, Kershnar A, Gupta S. Deficiency of monoclonal antibody (Leu 7) defined NK cells in newly diagnosed insulin-dependent diabetes mellitus. Immunol Lett.1984; 8: 89-91. PMID: 6746020
12. Shachner MS, Markmann JF, Bassiri H, Kim JI, Naji A, Barker CF. Direct assessment of the role of NK cells in autoimmune diabetes. J Surg Res.1992; 52: 601-604. PMID: 1382151
13. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A.2007; 104: 5115-5120. PMID: 17360338
14. Alba A, Planas R, Clemente X, Carrillo J, Ampudia R, Puertas MC, et al. Natural killer cells are required for accelerated type 1 diabetes driven by interferon-beta. Clin Exp Immunol.2008; 151: 467-475. doi: 10.1111/j.1365-2249.2007.03580.x PMID: 18190608
15. Gur C, Enk J, Weitman E, Bachar E, Suissa Y, Cohen G, et al. The expression of the beta cell-derived autoimmune ligand for the killer receptor nkp46 is attenuated in type 2 diabetes. PLoS One.2013; 8: e74033. doi: 10.1371/journal.pone.0074033 PMID: 24009765
16. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med.2002; 195: 343-351. PMID: 11828009
17. Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol.2013; 34: 182-191. doi: 10.1016/j.it.2013.01.003 PMID: 23414611
18. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature.2001; 409: 1055-1060. PMID: 11234016
19. Garg A, Barnes PF, Porgador A, Roy S, Wu S, Nanda JS, et al. Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J Immunol.2006; 177: 6192-6198. PMID: 17056548
20. Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E, et al. Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol.2004; 173: 2392-2401. PMID: 15294952
21. Ito K, Higai K, Sakurai M, Shinoda C, Yanai K, Azuma Y, et al. Binding of natural cytotoxicity receptor NKp46 to sulfate- and alpha2,3-NeuAc-containing glycans and its mutagenesis. Biochem Biophys Res Commun.2011; 406: 377-382. doi: 10.1016/j.bbrc.2011.02.050 PMID: 21329668
22. Ito K, Higai K, Shinoda C, Sakurai M, Yanai K, Azuma Y, et al. Unlike natural killer (NK) p30, natural cytotoxicity receptor NKp44 binds to multimeric alpha2,3-NeuNAc-containing N-glycans. Biol Pharm Bull.2012; 35: 594-600. PMID: 22466566
23. Halfteck GG, Elboim M, Gur C, Achdout H, Ghadially H, Mandelboim O. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol.2009; 182: 2221-2230. doi: 10.4049/jimmunol.0801878 PMID: 19201876
24. Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity.2000; 12: 721-727. PMID: 10894171
25. Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen-Gross T, Katz G, et al. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood.2004; 103: 664-672. PMID: 14504081
26. Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S, Zilka A, et al. NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol.2009; 183: 2610-2621. doi: 10.4049/jimmunol.0802806 PMID: 19635919
27. Rosental B, Brusilovsky M, Hadad U, Oz D, Appel MY, Afergan F, et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol.2011; 187: 5693-5702. doi: 10.4049/jimmunol.1102267 PMID: 22021614
28. Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, Achdout H, et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol.2006; 7: 517-523. PMID: 16565719
29. Nita II, Hershfinkel M, Kantor C, Rutter GA, Lewis EC, Sekler I. Pancreatic beta-cell Na+ channels control global Ca2+ signaling and oxidative metabolism by inducing Na+ and Ca2+ responses that are propagated into mitochondria. FASEB J.2014; 28: 3301-3312. doi: 10.1096/fj.13-248161 PMID: 24719357
30. Yu J, Mitsui T, Wei M, Mao H, Butchar JP, Shah MV, et al. NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. J Clin Invest.2011; 121: 1456-1470. doi: 10. 1172/JCI43242 PMID: 21364281
31. Glasner A, Ghadially H, Gur C, Stanietsky N, Tsukerman P, Enk J, et al. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol.2012; 188: 2509-2515. doi: 10.4049/ jimmunol.1102461 PMID: 22308311
32. Gur C, Enk J, Kassem SA, Suissa Y, Magenheim J, Stolovich-Rain M, et al. Recognition and killing of human and murine pancreatic beta cells by the NK receptor NKp46. J Immunol.2011; 187: 3096-3103. doi: 10.4049/jimmunol.1101269 PMID: 21849674
33. Paik SG, Fleischer N, Shin SI. Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. Proc Natl Acad Sci U S A.1980; 77: 6129-6133. PMID: 6449703
34. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 1976; 193: 415-417. PMID: 180605
35. O'Brien BA, Harmon BV, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model. J Pathol.1996; 178: 176-181. PMID: 8683386
36. Leiter EH. The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr Protoc Immunol. 2001; Chapter 15: Unit 15 19.
37. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010; 10: 301-316. doi: 10.1038/nri2761 PMID: 20414204
38. Colucci F, Cilio CM. Taming killer cells may halt diabetes progression. Nat Immunol.2010; 11: 111-112. doi: 10.1038/ni0210-111 PMID: 20084067
39. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol.2007; 7: 622-632. PMID: 17641665
40. Chatenoud L, Baudrihaye MF, Kreis H, Goldstein G, Schindler J, Bach JF. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol.1982; 12: 979-982. PMID: 6759145
41. Jewett A, Man YG, Tseng HC. Dual functions of natural killer cells in selection and differentiation of stem cells; role in regulation of inflammation and regeneration of tissues. J Cancer.2013; 4: 12-24. doi: 10.7150/jca.5519 PMID: 23386901
42. Narni-Mancinelli E, Ugolini S, Vivier E. [Natural killer cells: adaptation and memory in innate immunity]. Med Sci (Paris).2013; 29: 389-395. doi: 10.1051/medsci/2013294012 PMID: 23621934
43. Smith JA, Tso JY, Clark MR, Cole MS, Bluestone JA. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med.1997; 185: 1413-1422. PMID: 9126922
44. Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/ scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD. NON-Thy-1a donors. Diabetes.1993; 42: 44-55. PMID: 8093606
45. Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes. 2008; 57: 2883-2888. doi: 10.2337/db07-1817 PMID: 18971435
46. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity.2004; 20: 757-767. PMID: 15189740